373 related articles for article (PubMed ID: 22315442)
1. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.
Van Nostrand D; Khorjekar GR; O'Neil J; Moreau S; Atkins FB; Kharazi P; Mete M; Chennupati SP; Burman KD; Wartofsky L
J Nucl Med; 2012 Mar; 53(3):359-62. PubMed ID: 22315442
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of preparation with rhTSH or thyroid hormone withdrawal using ¹³¹I-whole body scans to identify metastases of differentiated thyroid cancer.
Liepe K
Int J Surg; 2015 Apr; 16(Pt A):107-112. PubMed ID: 25771100
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
[TBL] [Abstract][Full Text] [Related]
4. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons.
Freudenberg LS; Jentzen W; Petrich T; Frömke C; Marlowe RJ; Heusner T; Brandau W; Knapp WH; Bockisch A
Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2267-76. PubMed ID: 20661558
[TBL] [Abstract][Full Text] [Related]
5. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
6. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
Robbins RJ; Tuttle RM; Sharaf RN; Larson SM; Robbins HK; Ghossein RA; Smith A; Drucker WD
J Clin Endocrinol Metab; 2001 Feb; 86(2):619-25. PubMed ID: 11158019
[TBL] [Abstract][Full Text] [Related]
7. (124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer.
Van Nostrand D; Moreau S; Bandaru VV; Atkins F; Chennupati S; Mete M; Burman K; Wartofsky L
Thyroid; 2010 Aug; 20(8):879-83. PubMed ID: 20615132
[TBL] [Abstract][Full Text] [Related]
8. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Mazzaferri EL; Kloos RT
J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
[TBL] [Abstract][Full Text] [Related]
9. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
[TBL] [Abstract][Full Text] [Related]
11. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of recombinant human thyrotropin-stimulated ¹²³I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancer.
Alzahrani AS; AlShaikh O; Tuli M; Al-Sugair A; Alamawi R; Al-Rasheed MM
Clin Nucl Med; 2012 Mar; 37(3):229-34. PubMed ID: 22310247
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer.
Leboulleux S; Schroeder PR; Busaidy NL; Auperin A; Corone C; Jacene HA; Ewertz ME; Bournaud C; Wahl RL; Sherman SI; Ladenson PW; Schlumberger M
J Clin Endocrinol Metab; 2009 Apr; 94(4):1310-6. PubMed ID: 19158200
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod).
Leenhardt L; Leboulleux S; Bournaud C; Zerdoud S; Schvartz C; Ciappuccini R; Kelly A; Morel O; Dygai-Cochet I; Rusu D; Chougnet CN; Lion G; Eberlé-Pouzeratte MC; Catargi B; Kabir-Ahmadi M; Le Peillet Feuillet E; Taïeb D
J Clin Endocrinol Metab; 2019 Apr; 104(4):1020-1028. PubMed ID: 30398518
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
Vrachimis A; Schober O; Riemann B
Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
[TBL] [Abstract][Full Text] [Related]
18. Thyroid remnant ablation success and disease outcome in stage III or IV differentiated thyroid carcinoma: recombinant human thyrotropin versus thyroid hormone withdrawal.
Vallejo Casas JA; Mena Bares LM; Gálvez Moreno MA; Moreno Ortega E; Marlowe RJ; Maza Muret FR; Albalá González MD
Q J Nucl Med Mol Imaging; 2016 Jun; 60(2):163-71. PubMed ID: 26563902
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
[TBL] [Abstract][Full Text] [Related]
20. Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans?
Khorjekar GR; Van Nostrand D; Garcia C; O'Neil J; Moreau S; Atkins FB; Mete M; Orquiza MH; Burman K; Wartofsky L
Thyroid; 2014 Sep; 24(9):1394-9. PubMed ID: 24820222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
